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Abstract
Background—The magnitude of the as-
sociation between Helicobacter pylori and
incidence of gastric cancer is unclear. H
pylori infection and the circulating anti-
body response can be lost with develop-
ment of cancer; thus retrospective studies
are subject to bias resulting from classifi-
cation of cases as H pylori negative when
they were infected in the past.
Aims—To combine data from all case con-
trol studies nested within prospective
cohorts to assess more reliably the relative
risk of gastric cancer associated with H
pylori infection. To investigate variation in
relative risk by age, sex, cancer type and
subsite, and interval between blood sam-
pling and cancer diagnosis.
Methods—Studies were eligible if blood
samples for H pylori serology were col-
lected before diagnosis of gastric cancer in
cases. Identified published studies and two
unpublished studies were included. Indi-
vidual subject data were obtained for
each. Matched odds ratios (ORs) and 95%
confidence intervals (95% CI) were calcu-
lated for the association between H pylori
and gastric cancer.
Results—Twelve studies with 1228 gastric
cancer cases were considered. The associ-
ation with H pylori was restricted to non-
cardia cancers (OR 3.0; 95% CI 2.3–3.8)
and was stronger when blood samples for
H pylori serology were collected 10+ years
before cancer diagnosis (5.9; 3.4–10.3). H
pylori infection was not associated with an
altered overall risk of cardia cancer (1.0;
0.7–1.4).
Conclusions—These results suggest that
5.9 is the best estimate of the relative risk
of non-cardia cancer associated with H
pylori infection and that H pylori does not
increase the risk of cardia cancer. They
also support the idea that when H pylori
status is assessed close to cancer diagno-
sis, the magnitude of the non-cardia
association may be underestimated.
(Gut 2001;49:347–353)
Keywords: gastric cancer; Helicobacter pylori; cardia
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There is substantial evidence that infection
with the gastric bacterium Helicobacter pylori
plays a role in the development of gastric can-
cer.1 2 The magnitude of the risk of gastric can-
cer associated with infection is however unclear
and there have been suggestions that this risk
varies with sex,3 4 age,3 5 and the histological
subtype of the cancer.6 There is also evidence
that the excess risk is restricted to cancer
occurring at sites other than the gastric
cardia.4 5 7–9
Many studies have been conducted in an
attempt to address these issues. Retrospective
case control studies are however limited by the
fact that H pylori infection is, by necessity,
assessed after the development of cancer in the
cases. H pylori does not colonise areas of
cancer, intestinal metaplasia, or atrophy and
there is evidence that with the development of
advanced gastric disease the organism can be
lost from the stomach.10 With loss of infection,
the level of circulating anti-H pylori antibodies
will fall so that patients with gastric cancer may
be H pylori seronegative even though they have
been infected in the past (TU Kosunen,
personal communication).11 This will not occur
to the same extent in controls and, in the pres-
ence of such diVerential misclassification, esti-
mates of the association between H pylori and
gastric cancer will be biased downwards
making the results of retrospective studies dif-
ficult to interpret.
This problem can be overcome by conduct-
ing case control studies nested within prospec-
tive cohorts where blood samples used for H
pylori serology are collected before the develop-
ment of cancer. In 1991, three such studies
reported odds ratios (ORs) for the association
between H pylori infection and the subsequent
development of gastric cancer that ranged from
2.8 to 6.0.4 5 12 A number of other nested case
control studies have since been published7 13–18
and these have given less consistent results.
Two possible reasons for this inconsistency are
diVering proportions of cardia and non-cardia
cancers, and variable intervals between sample
collection and cancer diagnosis with short
intervals potentially leading to diVerential
exposure misclassification of cases as may
occur in retrospective studies. Initial support
for this latter hypothesis comes from a pooled
analysis of the data from the first three nested
case control studies which suggested that
higher ORs were seen when blood samples
were collected more than 10 years before the
diagnosis of cancer.19
Although there have been three previous
meta-analyses of published data examining the
association between H pylori infection and gas-
tric cancer,20–22 these have combined both pro-
spective and retrospective studies and/or have
Abbreviations used in this paper: CagA, cytotoxin
associated gene A; IgA (G), immunoglobulin A (G);
OR, odds ratio.
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been unable to separate cardia and non-cardia
cancers. We have therefore conducted a
collaborative reanalysis using individual sub-
ject data obtained from published and two
unpublished prospective studies. By pooling
these data we have been able to evaluate the
magnitude of this relationship more precisely
than previously and assess the relative risk in
relevant subgroups.
Methods
STUDY SELECTION
The analysis was restricted to case control
studies investigating the association between H
pylori infection and gastric adenocarcinoma
where samples for H pylori serology had been
collected prior to the diagnosis of gastric
cancer in the cases. Eligible studies were iden-
tified through a Medline search (1985–1999)
and through contact with investigators in the
area. By the end of 1999, 11 reports had been
published from nine studies.4–6 12–18 23 Results
have since been published from a study in
China24 and two further studies have been con-
ducted in Iceland (H Tulinius, personal
communication) and Finland (TU Kosunen,
personal communication). The investigators
from all 12 studies agreed to provide their data
for the present analysis. Results from an
additional prospective study in Japan25 have
also been published recently but individual
subject data from this study were not available
at the time of the present analyses.
DATASET
For each subject in their study, the investigators
provided the following information (or infor-
mation to allow calculation of the required
variables): case or control status, sex, H pylori
infection status (diagnosed by serology) and,
for cases, age at diagnosis, site and histological
type of the tumour (when available), and length
of time between collection of the blood sample
for H pylori serology and diagnosis of cancer.
For some studies, additional information was
available concerning cases who had gastric sur-
gery prior to the development of the cancer.
Identifiers for the matched sets were also
obtained in order to preserve the original
matching in the analyses. The matching
variables were sex, age, and date of sample col-
lection.
In two studies the controls were not matched
to the cases. For the second Finnish study,
controls greatly outnumbered cases and indi-
vidual matched case control sets were created
by dividing subjects into groups based on their
age when the blood samples were collected
(within a three year period). Each control was
then randomly allocated to one of the cases of
the same age at sample collection to give case
control sets matched on sex, age, and date of
sampling (both within about three years). In
the second Chinese study24 there was an excess
of older cases and younger controls and thus
individual age-sex matching was not eYcient.
For the overall analysis, cases and controls were
stratified by sex and age at blood sampling
(seven, five year bands) to give 14 matched sets
containing variable numbers of cases and con-
trols. For subsite specific analyses, cases within
each of the 14 sets were grouped so that each
group was homogeneous with respect to age at
diagnosis (10 year groups) and interval be-
tween blood sampling and diagnosis (five year
bands). Controls within each set were then
randomly allocated to one of the case groups in
the same set so that, as far as possible, each
group contained approximately equal numbers
of cases and controls. This process was carried
out separately for cardia and non-cardia cases
so that all 192 controls were matched to the 30
groups of cardia cases and 174 of the controls
were also matched to the 21 groups of
non-cardia cases (two of the 14 sex-age at sam-
pling sets did not contain a non-cardia case
thus these 18 controls were excluded from the
non-cardia analyses).
In each of the studies H pylori infection was
diagnosed by serology using an assay for anti-H
pylori IgG antibodies. DiVerent assays had
however been used and the cut oV point used
to determine H pylori seropositivity was that
used by the original investigators. The first
Chinese study had originally used an assay
developed in the UK.15 A local assay has since
been developed and validated in China (sensi-
tivity 99% and specificity 94%) and used for
the update of this study.16 These data were used
in the present analyses. In the first Finnish
study,14 results were based on serology for both
H pylori immunoglobulin (Ig) G and IgA but
the IgG data were included in the present
analyses for consistency.
Table 1 shows the total number of cases and
controls and the ORs for the association
between H pylori and gastric cancer in each of
the studies. The numbers diVer in some
instances from those originally published. In
the Californian study, two cases were subse-
quently found to have gastric lymphomas and
were thus excluded; the original report from
the first Chinese study included 85 cases15 and
80 of these plus 108 new cases were included in
the recent update,16 and while the original
report from the UK study12 included only 29
cases, additional cases have since been diag-
nosed,23 bringing the total to 56. The matched
analysis used here for the second Chinese study
gives slightly diVerent estimates from the origi-
nal unmatched analysis.24
H PYLORI SEROPREVALENCE
The studies had used diVering and sometimes
variable numbers of matched controls per case.
Because the seroprevalence of H pylori varied
across the studies, the prevalence in the control
group was therefore unduly influenced by
studies with the greatest numbers of controls
per case. To overcome this problem, the
seroprevalence in the controls was weighted by
the number of cases contributed by each study.
STATISTICAL ANALYSIS
The majority of analyses were conducted sepa-
rately for cardia and non-cardia cancers after
excluding cases known to have had previous
gastric surgery because this is also a strong
independent risk factor for gastric cancer.26 27
348 Helicobacter and Cancer Collaborative Group
www.gutjnl.com
Cases where the cancer site was not specified,
or where the tumour overlapped two or more
sites that included the cardia, were excluded
from site specific analyses. The definition of
cardia cancer was that used by the investigators
in the original studies. This should include only
tumours located within 2–3 cm of the oesoph-
agogastric junction and tumours extending
across the oesophagogastric border.
Conditional logistic regression was used to
estimate the association between H pylori and
cancer in order to preserve the individual
matching. Results are presented as maximum
likelihood estimates of the ORs and 95% con-
fidence intervals (CI). The change in the likeli-
hood ratio statistic on addition to the model of
a term for the interaction between H pylori sta-
tus and study centre was used to assess homo-
geneity across the studies. The same procedure
was used to evaluate diVerences in the eVect of
H pylori by sex, age group, histological subtype
of cancer, and time between sample collection
and cancer diagnosis. All tests of statistical sig-
nificance were two sided.
Results
Information from a total of 1228 gastric cancer
cases and 3406 controls from the 12 studies
was available for analysis. Table 1 and fig 1
show the basic characteristics of each study
together with the pooled OR from all studies
combined. There was some suggestion of
heterogeneity across the individual studies
although the statistical test was not convention-
ally significant (p=0.09). Overall, the matched
OR for the association between H pylori infec-
tion and the subsequent development of gastric
cancer was 2.36 (95% CI 1.98–2.81).
Table 2 and figs 2 and 3 show the OR for the
association with H pylori separately for cardia
and non-cardia cancers, after excluding cases
known to have had gastric surgery before they
developed cancer or where the cancer could
not be localised to a particular part of the
stomach. Combining the data gave an overall
OR of 2.97 (95% CI 2.34–3.77) for the associ-
ation between H pylori and non-cardia cancer
based on 762 cases and 2250 controls. There
was however statistically significant heterogen-
eity among the results (p=0.01) with the indi-
vidual OR ranging from 1.52 (0.66–3.53) in
Iceland up to 11.1 (2.51–49.4) in Sweden.
The results for cardia cancer were somewhat
more consistent and the heterogeneity test was
not statistically significant (p=0.12). Overall,
the OR between H pylori infection and risk of
cardia cancer was 0.99 (95% CI 0.72–1.35)
based on 274 cases and 827 controls. Three
studies (the two from China plus Norway)
contributed over two thirds of the cardia cancer
cases for this analysis.
In some subjects the cancer site was
unspecified or the cancer was so widespread it
overlapped two or more sites including the car-
dia. In this group which, like the group where
the site was specified, would probably include a
majority of non-cardia cancers, the OR for the
association between H pylori infection was 4.69
(95% CI 2.71–8.11). A high proportion of
Table 1 Characteristics of the individual studies and the overall association between Helicobacter pylori and gastric cancer
All cases Controls
Study
Mean (range)
age of cases at
diagnosis
Sex ratio
among cases
(% male)
Median
interval
(y)* Total
Hp +ve
(%) Total
Hp +ve
(%)
Matched
OR (95% CI)
UK12 23 54 (39–69) 100 8.7 56 67.9 174 41.4 3.47† (1.75–6.85)†
USA (California)4 68 (44–90) 69 15.0 111 84.7 111 60.4 3.70† (1.84–7.44)†
USA (Hawaii)5 72 (56–85) 100 13.8 109 94.5 109 76.1 6.00 (2.08–17.3)
Taiwan13 63 (43–80) 100 2.0 29 69.0 220 58.6 1.55 (0.68–3.54)
Finland I14 62 (32–85) 62 5.1 84 86.9 146 82.9 1.50 (0.70–3.22)
China I15 16 63 (49–76) 100 4.8 188 89.4 548 82.3 1.84 (1.08–3.11)
Sweden7 56 (38–70) 93 5.1 56 82.1 224 49.1 5.00 (2.34–10.7)
Japan17 69 (46–86) 58 3.6 45 91.1 225 75.6 3.38 (1.15–9.90)
Norway18 56 (34–68) 75 12.0 208 79.8 983 63.0 2.26 (1.55–3.28)
Iceland‡ 72 (55–89) 71 15.0 41 78.0 202 67.8 1.67 (0.76–3.65)
Finland II‡ 63 (52–75) 100 4.1 120 85.8 272 69.9 2.26 (1.26–4.05)
China II24 61 (36–75) 62 3.6 181 62.4 192 51.6 1.66† (1.08–2.54)
Total 62 (32–90) 82 6.0 1228 81.2 3406 66.1§ 2.36 (1.98–2.81)
*Interval between collection of blood sample used for H pylori serology and cancer diagnosis.
†Odds ratios (OR) diVer from published results due to changes in study sample (UK and California) and use of matching (China
II). Published results are UK OR 2.77 (95% confidence interval (CI) 1.04–7.97)15 and OR 4.0 (1.9–8.2)23; California OR 3.6 (1.8–
7.3)4; and China II OR 2.0 (1.3–3.2).24
‡Unpublished data.
§Weighted by the number of cases per study to allow for diVerent matching ratios.
Figure 1 Matched odds ratios (OR) and 95% confidence
intervals (CI) for the association between Helicobacter
pylori infection and gastric cancer, overall and by study.
The area of the square is proportional to the study size. The
diamond shows the OR value for all studies combined, with
95% CI represented by the horizontal points. +Unpublished
data.
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these cases (47%) came from the two Ameri-
can studies4 5 which could account for the
higher OR seen in this group.
INTERVAL BETWEEN SAMPLE COLLECTION AND
CANCER DIAGNOSIS
In the combined dataset a significantly increased
risk of non-cardia gastric cancer associated with
priorHpylori infection was seen for each interval
between sample collection and diagnosis (table
3). The strength of the association varied signifi-
cantly however with the time period (p for
trend=0.03). There was a 2.1–2.6-fold increase
in risk when samples were collected less than 10
years before the development of cancer com-
pared with a 5.9-fold increase in risk associated
with a positive H pylori test 10 years or more
prior to diagnosis (<10 years v >10 years;
p=0.002). A similar pattern was seen when the
analysis was restricted to the four studies
(Parsonnet and colleagues,4 Nomura and col-
leagues,5 Hansen and colleagues,18 and the
Iceland study) that covered the whole range
from less than five to more than 15 years.
In contrast, for cardia cancer, lower ORs were
seen with longer follow up (p for trend=0.09)
(table 4). There was a significantly reduced risk
of cancer (OR 0.46) associated with a positive H
pylori test 10 years or more prior to diagnosis in
comparison with a risk slightly greater than unity
(OR 1.23) when samples were collected less
than 10 years before the development of cancer
(p=0.01). However, 69% of the cardia cases
with 10 or more years follow up came from the
Norwegian study.
To allow for the possibility that cancers diag-
nosed in the first few months of follow up could
already have been present at the time of sample
collection, analyses were repeated excluding
cases diagnosed less than six months (23
non-cardia and four cardia cases) or within 18
months of sample collection (95 non-cardia and
26 cardia cases). This did not alter the results.
Considering all the gastric cancer cases, irre-
spective of subsite, the OR associated with a
positive H pylori test 10 years or more prior to
diagnosis was 3.12 (95% CI 2.23–4.35) and
was significantly greater (p=0.045) than that
obtained when samples were collected less than
Table 2 Association between Helicbacter pylori infection and non-cardia and cardia gastric cancer* data from 12 prospective studies
Study
Non-cardia cases Controls
Matched
OR (95% CI)
Cardia cases Controls
Matched
OR (95% CI)Total
Hp +ve
(%) Total
Hp +ve
(%) Total
Hp +ve
(%) Total
Hp +ve
(%)
UK12 23 9 66.7 27 44.4 2.88 (0.50–16.5) 12 33.3 36 30.6 1.15 (0.27–4.91)
USA (California)4 62 88.7 62 61.3 5.25 (1.80–15.3) 4 25.0 4 25.0 1.00 (0.06–16.0)
USA (Hawaii)5 74 95.9 74 75.7 8.50 (1.96–36.8) 5 40.0 5 80.0 —‡ —
Taiwan13 21 71.4 160 60.0 1.66 (0.61–4.51) 8 62.5 60 55.0 1.33 (0.31–5.79)
Finland I14 75 88.0 130 82.3 1.74 (0.75–4.03) 9 77.8 16 87.5 0.59 (0.08–4.30)
China I15 16 114 87.7 331 82.2 1.54 (0.82–2.89) 43 90.7 124 87.1 1.44 (0.43–4.92)
Sweden7 27 88.9 108 49.1 11.1 (2.51–49.4) 13 46.2 52 48.1 0.92 (0.27–3.16)
Japan17 38 89.5 190 73.7 3.02 (1.02–8.91) 4 100 20 85.0 —‡ —
Norway18 132 90.2 614 62.9 5.15 (2.83–9.37) 45 44.4 228 64.9 0.40 (0.20–0.77)
Iceland† 35 77.1 176 68.8 1.52 (0.66–3.53) 5 80.0 22 68.2 1.68 (0.18–15.5)
Finland II† 93 93.5 204 71.1 4.72 (1.98–11.3) 27 59.3 68 66.2 0.61 (0.22–1.70)
China II24 82 62.2 174 51.1 1.82 (1.03–3.22) 99 62.6 192 51.6 1.77 (1.05–2.97)
Total 762 86.0 2250 68.6§ 2.97 (2.34–3.77) 274 62.0 827 61.9§ 0.99 (0.72–1.35)
*Excludes all cases known to have had a partial gastrectomy or where the cancer could not be localised to a particular part of the stomach.
†Unpublished data.
‡In the Hawaiian study there were no case control pairs with a H pylori positive case and a negative control; in the Japanese study there were no H pylori negative cases.
§Weighted by the number of cases in each study to allow for the diVerent matching ratios of controls to cases.
OR, odds ratio; CI, confidence interval.
Figure 2 Matched odds ratios (OR) and 95% confidence
intervals (CI) for the association between Helicobacter
pylori infection and non-cardia gastric cancer, overall and
by study. The area of the square is proportional to the study
size. The diamond shows the OR value for all studies
combined, with 95% CI represented by the horizontal
points. +Unpublished data.
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Figure 3 Matched odds ratios (OR) and 95% confidence
intervals (CI) for the association between Helicobacter
pylori infection and cardia cancer, overall and by study.
The area of the square is proportional to the study size. The
diamond shows the OR value for all studies combined, with
95% CI represented by the horizontal points. +Unpublished
data.
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10 years before the development of cancer
(2.10 (95% CI 1.70–2.58)).
THE EFFECTS OF SEX, AGE, AND HISTOLOGICAL
SUBTYPE
There was a significant association between H
pylori and non-cardia cancer in all age groups
(table 3) but the magnitude of this association
was much greater among subjects aged
less than 60 than among those aged 60 or older
(p=0.006). This age eVect was independent of
the variation with time interval between sample
collection and diagnosis. In a model allowing
for the eVects of both age and time interval, the
OR for the association between H pylori and
gastric cancer was 2.2 (95% CI 1.3–3.7) times
greater among younger subjects (age <60) and
2.7 (1.5–5.1) times greater among those whose
blood samples were collected more than 10
years prior to diagnosis. After allowing for vari-
ation in both age and time interval, a test for
heterogeneity of the H pylori-gastric cancer
association across the 12 studies was no longer
statistically significant (p=0.2).
The association did not vary by sex (table 3).
Information on the histological subtype of the
tumour was only available for seven of the 12
studies (including Finland II).4 5 13 14 17 18 The
association with H pylori did not diVer greatly
between intestinal- and diVuse-type cancers
(p=0.5).
There was no statistically significant varia-
tion in the relationship between H pylori and
cardia cancer by age, sex, or histological type
(table 4). Although an inverse association was
seen only for intestinal-type and not diVuse-
type cancers, this diVerence was not statisti-
cally significant (p=0.3).
Discussion
This analysis provides evidence that the
increased risk of gastric cancer associated with
H pylori infection is restricted to cancers at sites
other than the gastric cardia. Estimates of the
risk of non-cardia gastric cancer associated
with H pylori infection were considerably
higher when blood samples for H pylori
serology were collected 10 years or more before
the diagnosis of cancer. This suggests that ret-
rospective case control studies, where H pylori
status is assessed after the diagnosis of cancer,
will underestimate the magnitude of the
association between H pylori and gastric cancer
as a result of loss of infection in cases with the
onset of disease.
Although overall there was an association
between increasing time interval between sam-
ple collection and cancer diagnosis and higher
OR, the OR peaked at 9.6 in the group with
samples collected 10–15 years before diagnosis
and then fell to 4.2 for the group with samples
collected more than 15 years before cancer
diagnosis. There was however considerable
overlap of the 95% CI for the OR and the dif-
ference was not statistically significant
(p=0.15). We have considered several possibili-
ties for the drop in OR in the group with the
longest interval, including diVerences in the
age structure and diVerential contributions
from the individual studies in the two groups,
but have not been able to explain this.
The matched analysis controls for potential
confounding by age, sex, and time of sample
collection. In addition, some of the individual
studies were also matched for race and/or area
of residence, and the UK subjects were from a
cohort that is relatively homogeneous with
respect to social class. Information on other
potential confounding factors, for example
socioeconomic and dietary factors, was not
available for the majority of studies included in
this analysis. In the original reports from the
Norwegian,18 first Chinese,15 16 and Finnish
Table 3 Association between Helicobacter pylori infection and non-cardia gastric cancer*
by interval between sample collection for H pylori serology and cancer diagnosis, age at
diagnosis, sex, and tumour histology‡
Cases Controls
Total Hp+ve† (%) Total Hp+ve† (%) Matched OR (95% CI)
Interval between sample collection and cancer diagnosis (y)
<5 334 82.6 999 66.2 2.56 (1.83–3.57)
5–9.9 205 85.4 624 72.0 2.09 (1.33–3.29)
10–14.9 103 95.1 293 63.1 9.56 (3.77–24.2)
15+ 120 88.3 334 65.9 4.15 (2.08–8.29)
<10 539 83.7 1623 68.4 2.39 (1.82–3.12)
10+ 223 91.5 627 64.6 5.93 (3.41–10.3)
Sex
Male 625 86.4 1839 68.4 2.98 (2.27–3.90)
Female 137 83.9 411 62.5 2.93 (1.76–4.88)
Age at diagnosis (y)
<50 67 89.6 251 54.2 7.10 (2.93–17.2)
50–59 206 87.4 718 65.2 3.94 (2.46–6.32)
60–69 313 82.7 886 70.9 1.98 (1.40–2.80)
70+ 176 88.6 395 71.6 3.13 (1.76–5.56)
Histological type‡
Intestinal 241 90.5 700 65.4 4.45 (2.74–7.24)
DiVuse 114 90.4 353 69.1 3.39 (1.70–6.76)
Total 762 86.0 2250 67.3 2.97 (2.34–3.77)
*Excludes all cases known to have had a partial gastrectomy and cases where the cancer could not
be localised to a particular part of the stomach.
†Percentages are not directly comparable across strata because diVerent studies contributed dif-
ferent numbers of cases to each stratum.
‡Information about histological type was only available for seven studies (the two from the USA,
the two from Finland, Taiwan, Japan, and Norway).
OR, odds ratio; CI, confidence interval.
Table 4 Association between Helicobacter pylori infection and cardia gastric cancer* by
interval between sample collection for H pylori serology and cancer diagnosis, age at
diagnosis, sex, and tumour histology‡
Cases Controls
Total Hp+ve† (%) Total Hp+ve† (%) Matched OR (95% CI)
Interval between sample collection and cancer diagnosis (y)
<5 133 68.4 340 66.5 1.21 (0.75–1.93)
5–9.9 93 63.4 273 60.4 1.26 (0.73–2.17)
10–14.9 26 42.3 108 60.2 0.48 (0.19–1.20)
15+ 22 40.9 106 60.4 0.44 (0.17–1.16)
<10 226 66.4 613 63.8 1.23 (0.86–1.75)
10+ 48 41.7 214 60.3 0.46 (0.23–0.90)
Sex
Male 210 61.9 680 63.2 0.98 (0.68–1.40)
Female 64 62.5 147 61.2 1.03 (0.55–1.92)
Age at diagnosis (y)
<50 33 45.5 97 50.5 0.90 (0.37–2.19)
50–59 86 61.6 311 62.1 0.94 (0.55–1.59)
60–69 115 63.5 317 67.5 0.84 (0.52–1.38)
70+ 40 72.5 102 62.7 2.23 (0.86–5.80)
Histological type‡
Intestinal 70 44.3 278 62.6 0.42 (0.24–0.75)
DiVuse 12 75.0 63 73.0 0.93 (0.21–4.10)
Total 274 62.0 827 62.9 0.99 (0.72–1.35)
*Excludes all cases known to have had a partial gastrectomy and cases where the cancer could not
be localised to a particular part of the stomach.
†Percentages are not directly comparable across strata because diVerent studies contributed dif-
ferent numbers of cases to each stratum.
‡Information about histological type was only available for seven studies (the two from the USA,
the two from Finland, Taiwan, Japan and Norway).
OR, odds ratio; CI, confidence interval.
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studies14 however, the data were adjusted for
potential confounders. In the Chinese and
Finnish studies the authors reported that
adjustment did not alter the results and, in
Norway, adjustment only slightly weakened the
positive association with non-cardia cancer
while slightly strengthening the inverse associ-
ation with cardia cancer. Thus although we
cannot rule out the possibility of residual con-
founding in the present analyses, it seems likely
that had adjustment for confounding been
possible, it would not have had an appreciable
eVect on the estimated ORs.
There was evidence of heterogeneity across
the results of the studies of the risk for
non-cardia cancer (p=0.01) although in seven
of the 12 studies the 95% CI around the point
estimate did not include the null value and in
all studies the point estimate was greater than
1.5. Some of this heterogeneity could be
explained by variation in the average interval
between sample collection and diagnosis and in
the average age of the participants in each
study as, after allowing for this, the heterogen-
eity was reduced and was no longer statistically
significant (p=0.2).
We suggest therefore that the approximately
sixfold increased risk seen in the group
followed for 10 years or more is the best
estimate of the magnitude of the relative risk of
non-cardia gastric cancer associated with H
pylori infection. This estimate is considerably
higher than the OR of 2.0–3.1 reported in pre-
vious meta-analyses.20–22
Results from another study in Japan25 have
been published since this pooling project and
could not be included in the analysis. This
study reported a positive association for
non-cardia cancer (OR 3.66; 95% CI 1.12–
11.92) and little eVect for the 10 patients with
cancer in the “proximal one third of the stom-
ach” (OR 1.29; 95% CI 0.28–6.09). Inclusion
of this additional study would thus have had
little eVect on the results.
A retrospective case control study, con-
ducted in the USA, has shown a lower risk for
oesophageal and cardia adenocarcinomas asso-
ciated with H pylori infection although this was
significant only for infection with cytotoxin
associated gene A (CagA) positive strains of H
pylori.9 CagA serology data are not available for
all of the studies included in the present analy-
sis and therefore this question was not
addressed in this paper. It is however necessary
to explain why, in our results, H pylori appears
to have no eVect on the development of cardia
cancers while increasing the risk of cancers
throughout the rest of the stomach. Reflux
oesophagitis has been associated with oesopha-
geal and cardia adenocarcinomas28 and this
suggests that gastric acid exposure might play a
role in the aetiology of these cancers. The
widespread gastritis and atrophy, which are a
consequence of H pylori infection and increase
the risk of non-cardia gastric cancer, may
reduce gastric acidity and the extent of reflux
disease. It is also of note that while the
seroprevalence of H pylori29 and gastric cancer
incidence rates30 appear to be falling over time,
the incidence of cardia cancer and oesophageal
adenocarcinoma appears to be on the
increase.31–36
Only four studies in our analysis included
more than 20 cases with cardia cancer and, of
these, the two from China indicated an elevated
risk associated with infection (ORs 1.44 and
1.77) while two from Europe indicated a
reduced risk (ORs 0.40 in Norway and 0.61 in
Finland II). Overall these results are consistent
with the summary odds ratio of 0.99 indicating
no eVect of infection but it is also possible that
there may be a divergence of eVect between
Europe and China. Although we formally
tested for, and found no evidence of, between
study heterogeneity for cardia cancer,
heterogeneity tests have relatively little power
to detect small to moderate variation in eVect.
It should be emphasised that a conclusion of
diVerent eVects between populations is entirely
data derived and requires independent confir-
mation from other studies.
Conclusions
We believe that the best estimate of the magni-
tude of the association between H pylori infec-
tion and the subsequent risk of non-cardia gas-
tric cancer is about sixfold seen in the group of
subjects whose samples for H pylori serology
were collected 10 or more years prior to the
development of cancer. Estimates of relative
risk appear to be diluted when H pylori
infection is assessed closer to the time of cancer
diagnosis. The magnitude of this risk varies
with age; the eVect is reduced in the older age
groups, presumably because of increased sero-
prevalence among the older controls because
there is little change in the seroprevalence in
cases with age. Assuming an average prevalence
of H pylori of 35% in developed countries and
85% in developing countries, an OR of 5.9
suggests that between about 65% and 80%,
respectively, of non-cardia gastric cancers are
attributable to H pylori infection and therefore
potentially preventable by control of the infec-
tion. H pylori infection does not however
appear to increase the risk of cardia cancer.
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